The life-science incubator in Geneva

The life-science incubator in Geneva

The life-science incubator in Geneva

24

Companies since 2004

118

Collaborators in the Eclosion environment

300

Millions CHF of capital raised by portfolio companies

1

IPO in April 2016

Molecular

Mission

The Foundation Eclosion mission is to foster entrepreneurs in translating their life science innovation into economic value and jobs in the Geneva’s region.

Offer

We provide entrepreneurs with the key resources required to bridge the gap from laboratory to start-up:

  • LABORATORY AND OFFICE INFRASTRUCTURE
  • BUSINESS AND SCIENTIFIC SUPPORT
  • FINANCIAL SUPPORT
  • OTHER SERVICES

Offer

We provide entrepreneurs and scientists with the key ressources to cross the bridge frpom laboratory to the start-up:

  • Infrastructure
  • Business and scientific support
  • Funding
  • Other services
Infrastructure

Laboratory and office infrastructure

Eclosion incubates projects and hosts start-up companies utilising more than 800 sq m of laboratories located at the (CTN – Centre des Technologies Nouvelles) and 500 sq m of offices at both the CTN and Campus Biotech Innovation Park (CBIP).

Laboratory and office infrastructure

Eclosion incubates projects and hosts start-up companies utilizing more than 800 sq m of laboratories located at the (CTN – Centre des Technologies Nouvelles) and 500 sq m of offices at both the CTN and the Campus Biotech Innovation Park (CBIP).

Infrastructure

Business and scientific support

Eclosion provides the support to entrepreneurs from seasoned life science and finance professionals, including its Advisory Board, to assist in the design and implementation of development plans, as well as best positioning companies towards the market.

Business & Scientific Support

Business and scientific support

Eclosion provides the support to entrepreneurs from seasoned life science and finance professionals, including its Advisory Board, to assist in the design and implementation of development plans, as well as best positioning companies towards the market.

Business & Scientific Support

Financial Support

Eclosion services include; financial support to conduct key experiments and access to the finance community, including Eclosion fund, to seed and fund start-up companies.

Financial Support

Eclosion services include; financial support to conduct key experiments and access to the finance community, including Eclosion fund, to seed and fund start-up companies.

Other services

Eclosion also provides a wide range of additional services, including administration, accounting and payroll support, as well as access to business intelligence databases.

Other Services

Other services

Eclosion also provides a wide range of additional services, including administration, accounting and payroll support, as well as access to business intelligence databases.

Other Services

Community

Eclosion is fully integrated in the vibrant life-science community of Geneva and Switzerland, including economic promotion agencies, investors, research institutes, and the Swiss Commission for Technology and Innovation.

Portfolio

Their success is our success:

Product companies at various stages of development, addressing high-unmet medical needs in various therapeutic areas including oncology, neurology, gastroenterology, rare diseases and cardiovascular diseases.

Service companies including proprietary technology and life science consulting.

Leadership

The team

Christophe Guichard

Christophe is dedicating his energy and passion to life-science start-up companies as Director of Eclosion since 2008. He is also contributing his experience in managing finance and legal activities and served as CFO for companies including GeNeuro, GenKyoTex and DepGen, raising over CHF 150m in equity. Prior to joining Eclosion, he held various corporate finance positions including CFO of a European listed company and manager with KPMG-Salustro, building organizations and performing M&A transactions and two IPOs. Christophe is a graduate from EDHEC Business School and from Harvard Business School. He also holds a postgraduate degree in Finance and Accounting (DESCF).

Yann Dean

Yann Dean holds a PhD from the University Of Wales College Of Medicine, Cardiff, UK. He has 15 years of experience in the biotech sector. Before joining Eclosion, Yann worked at NovImmune SA, where he developed one therapeutic monoclonal antibody from research to clinical phase IIa as Project Leader and participated in the development (from bench to bedside) of five other monoclonal antibodies as Preclinical Manager. Yann has published several peer-reviewed scientific articles and authored multiple patents related to the validation of therapeutic targets and development of biological drugs.

Farid Bouzidi

Farid joined Eclosion as Scientific Director. Farid has more than 15 years’ experience in Business/Corporate/Product Development across a range of clinical indications including CNS, autoimmune diseases, oncology, and infectious diseases. With his experience at Institut Pasteur, he has a strong emphasis on entrepreneurship, value creation and incubation. He has worked in many organisations including Genentech, Roche, AC Immune and as an independent consultant covering projects from discovery to clinical development and marketed products. Farid is currently a senior advisor to the Institut Pasteur for innovative projects. Farid obtained his Ph.D. in Biophysics and Biochemistry from CEA and MBA from EM-Lyon, France.

Foundation Council

Ex-CEO of DuPont de Nemours International à Genève M. Schriber is the founder of “Réseau” non-for profit organization dedicated to promote the creation and development of high-tech start-ups. Mr. Schriber is part of the management of ETeCH-Zurich, board member at UNITEC (IP department), academic board member at UNIGE and board member at Geneva airport. Mr. Schriber is the chairman at Foundation Eclosion.

Jesús began his career in 1983 at the World Economic Foundation, and in 1989 at McKinsey & Co where he led studies in the pharmaceutical and food industries. By 1993, he chose the entrepreneurial path by creating, investing and leading start-ups in Switzerland and the United States. He was for example a co-founder of LeShop in 1996, which became the Swiss leader in e-commerce and sold to Migros.

In 2003, he created Eclosion, a public-private partnership for translating scientific discoveries in the field of life sciences into innovative drugs with disruptive potential. Jesús holds a bachelor’s degree in industrial sciences, a master in law from Geneva University and an MBA from Harvard Business School. He serves on the board of several biotech companies and industrial and business associations.

Professor Offord taught and researched at the Universities of Cambridge and Oxford, U.K. from 1962-1980, collaborating with, among others, the Nobel Prize winners Frederick Sanger, César Milstein, Dorothy Hodgkin and Aaron Klug. In 1980 he became a Departmental Director at the Faculty of Medicine, University of Geneva, and later served as President of the School of Basic Medicine there. Robin became an Emeritus Professor in October 2005. He was a co-founder of the Swiss Institute for Bioinformatics. He served for ten years as a member of the Geneva government’s Council for Regional Economic Development. He is Chairman of the Board of Trustees of the Torrey Pines Institute for Molecular Studies (Port St Lucie, Florida and San Diego) and is the first non-US President of the American Peptide Society. Robin Offord shared the 2002 “Man of the Year, Switzerland” award of the Swiss financial newspaper L’agefi and in 2005 received the American Peptide Society’s Makineni Award. Mr. Offord serves as a board member and is Chairman of the Advisory Board of Eclosion

Professor Schlegel gained a PhD at Eidgenössische Technische Hochschule Zürich, and continued his career at the National Institutes of Health in Bethesda, Maryland alongside Nobel Prize winner Martin Rodbell. He has conducted his own research in intracellular signalling at Geneva University since 1980. As director of the “Fondation Pour Recherches Médicales” since 1994, he has given the institution a major part in biotechnology transfer by assimilating several start-ups, including NovImmune SA.

Schlegel holds numerous international posts, particularly in Japan, where he was a visiting professor at Kobe University in 1997 and Osaka University in 2004. He has cofounded a number of start-ups, including Europroteome AG, where he was president of the board of directors.

Emanuela Dose Sarfatis qualified as an attorney. She managed the legal department of a private bank in Lausanne and was a member of her local council before joining Geneva cantonal council in 1994.

Ms Dose Sarfatis is a member of the directorate general for economic affairs within the department of regional, economic and health affairs, delegated by the cantonal counsel to the boards of the Fondation d’Aide aux Entreprises, the Coopérative Romande de Cautionnement en Faveur des PME, the Fondation Genevoise pour l’Innovation Technologique, and Eclosion SA. She also advises the Conseil de Surveillance du Marché de l’Emploi, the Commission Tripartite Préavisant les Demandes d’Autorisations de Travail, the Conseil Interprofessionnel pour la Formation, and the Conseil de Fondation de l’Ecole Internationale de Genève.

After a PhD in chemistry at the University of Geneva, Gérard Gandillon has done all his career by Givaudan, leader in the fragrance and flavor business. In this company he has successively held various positions in the technical field, leading all the different operational departments, starting with chemical production of fragrance synthetic ingredients and following with Environment/Health/Safety as well as engineering and maintenance, quality control, purchasing, transport, etc.

He is the founder and director of a new company created in March 2013, “GAP Conseils”. This company makes studies, trainings in various fields such as industrial safety, energy consumption reduction, occupational health and safety.

Gérard Gandillon is also Chairman of the Industrial Association for Life Sciences in Geneva (in French: Association Industrielle Genevoise des Sciences de la Vie or AIGSV), regrouping the companies active in the pharma business, chemistry and biotechnologies. He is also judge at the Labour Tribunal of Geneva

Advisory board

Professor Offord taught and researched at the Universities of Cambridge and Oxford, U.K. from 1962-1980, collaborating with, among others, the Nobel Prize winners Frederick Sanger, César Milstein, Dorothy Hodgkin and Aaron Klug. In 1980 he became a Departmental Director at the Faculty of Medicine, University of Geneva, and later served as President of the School of Basic Medicine there. Robin became an Emeritus Professor in October 2005. He was a co-founder of the Swiss Institute for Bioinformatics. He served for ten years as a member of the Geneva government’s Council for Regional Economic Development. He is Chairman of the Board of Trustees of the Torrey Pines Institute for Molecular Studies (Port St Lucie, Florida and San Diego) and is the first non-US President of the American Peptide Society. Robin Offord shared the 2002 “Man of the Year, Switzerland” award of the Swiss financial newspaper L’agefi and in 2005 received the American Peptide Society’s Makineni Award. Mr. Offord serves as a board member and is Chairman of the Advisory Board of Eclosion.

Andrew has twenty years of experience in drug discovery and early clinical development within pharmaceutical and biotechnology sectors. Before joining Eclosion Andrew was VP and Head of exploratory projects group at Shire. Andrew has a Ph.D. from the National Institute for Medical Research (UK), carried out post-doctoral studies at Johns Hopkins School of Medicine (USA) and completed an MBA with Warwick Business School (UK).

Timothy Wells is the chief scientific officer for Malaria Ventures. Before joining that organisation, he was senior executive vice president of research for Serono, conducting clinical trials on a number of innovative molecules. From 1997 to 2007, he worked at Glaxo’s molecular biology institute in Geneva, where he managed research into protein biochemistry and chemotactic cytokines.

 

An enzymologist by training, Wells’ research interests included the relationships between protein structure and function, and the role of cytokines in controlling host responses. He has contributed to over 180 scientific publications and several patent registrations. Wells gained a doctorate in chemistry from London’s Imperial College for his research into protein engineering under the supervision of Sir Alan Fersht, and then obtained an ScD from Cambridge University for his work on the cytokine biology. He is a member of the Royal Society of Chemistry.

Dr le Cotonnec obtained a bachelor’s degree in engineering, a doctorate in medicine and a master’s in statistics in Paris. For 14 years, he occupied senior positions in the pharmaceutical industry, including posts at Novartis and Serono. In 1995 he founded Triskel Integrated Services SA, a company that defines and implements strategies to develop and register medical products in Europe and the USA, working in strategic cooperation with traditional contract research and manufacturing organisations. He has been involved in the development and registration of over ten drugs, including several blockbusters.

Professor Dennis Hochstrasser is a practising internist and clinical chemist. He manages the clinical pathology department and the central clinical chemistry and biological examination laboratories at Geneva’s university hospitals, supervises the computational activities of the medicine faculty at Geneva University, and runs a leading international multidisciplinary research group in proteomics. Prof. Hochstrasser cofounded the Institut Suisse de Bioinformatique, GeneBio SA, and Geneprot Inc.

Karl-Heinz Krause is Professor of Medicine at the Faculty of Medicine & University Hospitals of Geneva, as well as honorary professor at the Bejing Hospital, China. He received his MD from the Ludwig-Maximilian University (Munich) in 1982. From 1982 to 1989, he received clinical training in internal medicine and infectious diseases at the Universities of Munich, Geneva and Iowa. Starting in 1984, Prof. Krause has been actively involved in inflammation research. Since 1998, he has focused his research further on mechanisms of aging and treatment of age-associated diseases, in particular on the NOX family of NADPH oxidases as a pathophysiologically important source of oxygen radicals. He is an elected member of the Swiss Academy of Medical Sciences and the American Society for Clinical Investigation

Dr Oern R. Stuge is director of Impulse Dynamics NV. He was first vice president, a member of the operating committee member and president for Europe, Canada, Latin America and emerging markets at Medtronic Inc. His numerous life sciences projects in areas such as Rx, Dx, nutrition and medical devices have given significant experience and a reputation as a leading force in this domain.

 

Dr Stuge was a member of Medtronic’s management team for 12 years, serving as president for cardiac surgery and president for Europe and Central Asia, where he was responsible for transforming the cardiac surgery business and accelerating the growth of Medtronic companies in Europe with cardiovascular, neurological and spinal franchises.

 

Before joining Medtronic, Dr Stuge served first as CEO of Medinor A/S, a Norwegian medical technology company, and then for Abbott Laboratories, where he was regional director and managing director for the Netherlands and the Nordic countries. He is a principal adviser to HealthCap, a life sciences investment fund with $1.5 billion under management; a member of the supervisory board of Mediq BV, an international medicines and pharmaceuticals distributor; and a director of Nobel Biocare AG, a world leader in dental implants. Dr Stuge graduated in medicine at Oslo University, and gained an MBA from the IMD business school in Lausanne

Mr. Jean-Marc Leroux is the Chief Innovation Officer of Covance and General Manager CCLS Europe. He has been in this role since February 2014.

Throughout his 15-year career with Covance, Mr. Leroux has been instrumental in shaping the company’s Central Laboratory strategy and securing new talent and technology to deliver strategic advances in that business. He progressed through various leadership positions in Central Laboratories, including Vice President of Global Laboratory Operations and Scientific/ Technical Affairs, Vice President for all Central Laboratory Global Operations (Laboratory, Sample Management/Lab Pre-analytical Services, Investigator Site Support, Logistics, and Kit Production) and most recently Vice President of Global Innovation & GM Europe for CLS. He has always been dedicated to identifying new technology and business innovations throughout his career at Covance, advocating for state-of-the-art laboratory automation, advances in informatics and new services like biomarkers and point-of-care devices.

Prior to joining Covance, Mr. Leroux launched his own network of diagnostics labs in France, implemented the central laboratory division for clinical trials at Pasteur Institute and worked in different European CROs and served as a board member for Eclosion and Metaphora.

Headed by Mr. Leroux, Covance’s Geneva site has earned a string of awards for carpooling and reducing biohazard waste, including First Prize of Economy in 2014 from Geneva Chamber of Commerce.

Mr. Leroux holds doctorate degrees in pharmaceutics (Sc. Pharmaceutics) and pharmacy (PharmD); a National Diploma in biochemistry, hematology, bacteriology and immunology; and a University Diploma in biological and medical engineering. He is the first prize recipient of the Behring Award in Biology and “Ancien interne des Hopitaux”.

Mr. Leroux lives in Geneva with his wife and has five children.

Dr. Frédéric Levy  and his team manage the Evaluation of innovative therapeutics at Debiopharm International SA in Lausanne, Switzerland. He obtained his doctoral degree in biochemistry at the Karolinska Institute in Stockholm, Sweden and spent several years as a postdoctoral fellow at the California Institute of Technology in Pasadena. He moved then to Switzerland to take a position at the Lausanne Branch of the Ludwig Institute for Cancer Research, where he successively awarded a Young Investigator Award of the Cancer Insitute, a Professorship of the Swiss National Funds, an Associate Membership of the Ludwig Institute and an Associate Professorship of the University of Lausanne. His area of expertise is drug development in oncology, immunology and infectious diseases. During his career, Frédéric Levy was Vice-President of the Swiss Society of Biochemistry, Board Member of the Platform Biology of the Swiss Academy of Science, jury member of the Friedrich Miescher Award and Board Member of the FEBS.

Submit your project

SUBMIT YOUR PROJECT

Get in touch

CONTACT US
© 2016 Fondation Eclosion
All rights reserved
Webdesign: Comstone / Pierre Chassany
WordPress Development: Olivier Gisiger